N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity

Neuropsychopharmacology

Volumn 33, Issue 10, 2008, Pages 2303-2312

  Jensen, Niels H ^a   Rodriguiz, Ramona M ^b   Caron, Marc G ^b   Wetsel, William C ^b   Rothman, Richard B ^c   Roth, Bryan L ^a,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Division of Medicinal Chemistry and Natural Products

Author keywords

Antidepressant; Antipsychotic; N Desalkylquetiapine; Norepinephrine reuptake inhibitor; Quetiapine

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; DIBENZO[B,F][1,4]THIAZEPIN 11 ONE; DIBENZOTHIAZEPINE DERIVATIVE; DRUG METABOLITE; G PROTEIN COUPLED RECEPTOR; HISTAMINE H1 RECEPTOR; ION CHANNEL; MUSCARINIC M1 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M5 RECEPTOR; NEUROTRANSMITTER TRANSPORTER; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; NORQUETIAPINE; QUETIAPINE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN 7 RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BRAIN CHEMISTRY; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DEPRESSIVE DISORDER; DIBENZOTHIAZEPINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RATS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 49549104014     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301646     Document Type: Article

References (43)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-1696.
2. 35S]GTPgammaS binding in rat hippocampal membranes. Eur J Pharmacol 343: 303-312.
3. Armbruster BN, Roth BL (2005). Mining the receptorome. J Biol Chem 280: 5129-5132.
4. Balit CR, Isbister GK, Hackett LP, Whyte IM (2003). Quetiapine poisoning: a case series. Ann Emerg Med 42: 751-758.
5. 1A agonist (PRX-00023) for the treatment of anxiety and depression. J Med Chem 49: 3116-3135.
6. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH et al (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162: 1351-1360.
7. Cohrs S, Rodenbeck A, Guan Z, Pohlmann K, Jordan W, Meier A et al (2004). Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl) 174: 421-429.
8. Cryan JF, Mombereau C, Vassout A (2005). The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29: 571-625.
9. 1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl) 178: 451-460.
10. Davis PC, Wong J, Gefvert O (1999). Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection. J Pharm Biomed Anal 20: 271-282.
11. DeVane CL, Nemeroff CB (2001). Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 40: 509-522.
12. Dranovsky A, Hen R (2006). Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry 59: 1136-1143.
13. Fukui M, Rodriguiz RM, Zhou J, Jiang SX, Phillips LE, Caron MG et al (2007). Vmat2 heterozygous mutant mice display a depressive-like phenotype. J Neurosci 27: 10520-10529.
14. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 135: 119-126.
15. Goldstein JM, Arvantis LA (1995). ICI 204,636: a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of Phase II clinical trials. CNS Drug Rev 1: 50-73.
16. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB (2006). Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 61: 58-69.
17. Gunasekara NS, Spencer CM (1998). Quetiapine: a review of its use in schizophrenia. CNS Drugs 9: 325-340.
18. 7 receptor suggest therapeutic potential in depression. Neuropharmacology 48: 492-502.
19. Jain R (2004). Single-action versus dual-action antidepressants. Prim Care Companion J Clin Psychiatry 6: 7-11.
20. Jensen NH, Roth BL (2007). Massively parallel screening of the receptorome. Comb Chem High Throughput Screen (in press).
21. Johnson DE, Yamazaki H, Ward KM, Schmidt AW, Lebel WS, Treadway JL et al (2005). Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 54: 1552-1558.
22. 1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 104: 3456-3459.
23. 1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519-526.
24. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR (2007). Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 46: 359-388.
25. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 1159-1172.
26. Orsetti M, Canonico PL, Dellarole A, Colella L, Di Brisco F, Ghi P (2007). Quetiapine prevents anhedonia induced by acute or chronic stress. Neuropsychopharmacology 32: 1783-1790.
27. Pogorelov VM, Rodriguiz RM, Insco ML, Caron MG, Wetsel WC (2005). Novelty seeking and stereotypic activation of behavior in mice with disruption of the Dat1 gene. Neuropsychopharmacology 30: 1818-1831.
28. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT (2004). Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 75: 234-241.
29. + channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 25: 133-166.
30. Roth BL (2006). Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? Dialogues Clin Neurosci 8: 303-309.
31. Roth BL (2007). Drugs and valvular heart disease. N Engl J Med 356: 6-9.
32. Roth BL, Sheffler DJ, Kroeze WK (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3: 353-359.
33. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI et al (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
34. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102: 2836-2841.
35. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L et al (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356: 1711-1722.
36. Setola V, Roth BL (2003). Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants. Mol Pharmacol 64: 1277-1278.
37. 3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 27: 289-304.
38. Song M, Clark M (2006). Development and evaluation of an in silico model for hERG binding (supporting Information). J Chem Inf Model 46: 392-400.
39. Strachan RT, Ferrara G, Roth BL (2006). Screening the receptorome: an efficient approach for drug discovery and target validation. Drug Discov Today 11: 708-716.
40. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A et al (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 26: 600-609.
41. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C et al (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60: 1079-1088.
42. Wang YM, Gainetdinov RR, Fumagalli F, Xu F, Jones SR, Bock CB et al (1997). Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19: 1285-1296.
43. Yan B, He J, Xu H, Zhang Y, Bi X, Thakur S et al (2007). Quetiapine attenuates the depressive and anxiolytic-like behavioural changes induced by global cerebral ischemia in mice. Behav Brain Res 182: 36-41.